Immune failure, infection and survival in chronic lymphocytic leukemia in Denmark

We are very thankful to Crassini et al. for evaluating the impact of infections on overall survival (OS) in their long-term follow-up cohort as a commentary to our paper on predicting infection in CLL.1 They report a significant association between infection during the first year of observation and OS. In the last couple of years, our groups and others have examined the immune dysfunction, both in general but particularly hypogammaglobulinemia, in patients with CLL. Both groups have demonstrated poor survival among CLL patients with hypogammaglobulinemia. Now, Crassini et al. demonstrate that identifying immune dysfunction in terms of early infection is predictive of poor OS.

Within our nationwide cohort of patients diagnosed with CLL in Denmark since 2008, we re-analyzed OS and treatment free survival (TFS) based on whether patients have had an infection during the first year after diagnosis or not.2 All patients alive and treatment-naïve one year after CLL diagnosis were included for this analysis. As demonstrated below, the association (P<0.001) between infection, OS and TFS, as reported by Crassini et al., could be validated in this nationwide cohort (Figure 1 A and B).

Figure 1.Kaplan-Meier curves for A) overall survival and B) treatment free survival. (A) Kaplan-Meier curve from one year after diagnosis until death or end of follow up for all included patients grouped by patients having an infection during the first year (red). (B) Kaplan-Meier curve from one year after diagnosis until death, treatment or end of follow up for all included patients grouped by patients having an infection during the first year (red).

When discussing immune dysfunction in CLL in the era of targeted therapies, three important questions warrant further assessment: